~~<i id='9673DEC1CB'><strike id='9673DEC1CB'><tt id='9673DEC1CB'><pre id='9673DEC1CB'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

leisure time

author：entertainment 2025-09-30 15:16:42 - browse：5

Adam's take main illustration — Molly Ferguson/STAT

Shares of Apellis Pharmaceuticals are rebounding, driven by a growing belief among some investors that the serious safety issue that has derailed Syfovre, the company’s eye disease treatment, is receding.

Declaring the crisis over is premature, but that could change with more uneventful weeks. Apellis has been a takeout target before, and may be again, at an acquisition price nearly twice its current market value.

Apellis shares rose 32% last week, with most of the gains coming Friday on heavy trading volume. The reason: There have been no new cases of retinal occlusive vasculitis, or ROV, reported in people receiving injections of Syfovre.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： CMS should re

entertainment

hotspot

explore

focus

explore

AdobeOneofthehardestpartsaboutgettinganX-rayoraCTscanisthewait.Sometimesittakesdays,orevenweeks,form

WSS

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

FDA needs staff influx to meet gene therapy needs, Marks says

Pregnancy discrimination could be enabled by AI

Why sickle cell disease is getting the first CRISPR treatment

Pfizer plans to depart BIO

Congenital heart disease patients face new threat of heart failure

focus

leisure time

entertainment

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Patients' immediate access to test results puts radiologists in a bind

United colonoscopy coverage change 'may cost lives,' doctors say

Chemotherapy shortages won’t get better under Biden’s latest plan

Malaria cases in Florida and Texas: Here’s what you need to know

Supreme Court wrestles with OxyContin maker's bankruptcy deal

Virginia high school admissions case could be legal follow

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

Medical leaders decry Supreme Court decision on affirmative action

Americans' trust in science, scientist continues decline: Report

hotspot

SCOTUS to consider access to abortion pill mifepristone

After sickle

In diabetes hearing, Sanders takes on a new foe: food makers

SCOTUS to consider access to abortion pill mifepristone

After sickle

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

explore

explore

focus

explore